Physician_Profile_ID,Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_Name,Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_State,Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_ID,Total_Amount_of_Payment_USDollars,Date_of_Payment,Form_of_Payment_or_Transfer_of_Value,Record_ID,Name_of_Associated_Covered_Drug_or_Biological1,Name_of_Associated_Covered_Drug_or_Biological2,Name_of_Study,Research_Information_Link,Context_of_Research
5433,"Takeda Development Center Americas, Inc.",IL,100000000338,82.60,08/26/2013,"Cash or cash equivalent",106113532,Metformin,"","Add-on metformin study with active comparator to Januvia  2nd head-to-head study against Januvia","",""
5433,"Takeda Development Center Americas, Inc.",IL,100000000338,70.80,12/22/2013,"Cash or cash equivalent",106113519,"","","Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy & Safety of Daily Oral TAK-875 25 mg & 50 mg Compared to Placebo When Used in Combination with Sitagliptin","",""
5433,"Takeda Development Center Americas, Inc.",IL,100000000338,59.00,12/22/2013,"Cash or cash equivalent",106113503,"","","Multicenter, Randomized, DB, Placebo-Controlled, P3 Study to Evaluate CV Outcomes of TAK-875, 50 mg in Addition to SOC in Subjects with T2DM and with CV Disease or Multiple Risk Factors for CV Events","",""
5433,"Takeda Development Center Americas, Inc.",IL,100000000338,35.40,11/21/2013,"Cash or cash equivalent",106113517,"","","Placebo controlled, Doubled Blind Parallel-Group study to evaluate the Glycemic effects and safety of 25 mg BID and 50 mg QD of TAK-875 on HbA1c reduction and other measures of glycemic control","",""
